Cargando…

TNF-α Production by Monocytes Stimulated With Epstein-Barr Virus–Peptides as a Marker of Immunosuppression-Related Adverse Events in Kidney Transplant Recipients

INTRODUCTION: Infections and cancers now outnumber rejection as a cause of morbidity in transplant recipients, likely as a result of over-immunosuppression. Currently, there is no clinical tool to detect over-immunosuppression. We recently reported that tumor necrosis factor alpha (TNF-α) production...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouchard-Boivin, François, Désy, Olivier, Béland, Stéphanie, Houde, Isabelle, De Serres, Sacha A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829185/
https://www.ncbi.nlm.nih.gov/pubmed/31701054
http://dx.doi.org/10.1016/j.ekir.2019.07.007
_version_ 1783465494701932544
author Bouchard-Boivin, François
Désy, Olivier
Béland, Stéphanie
Houde, Isabelle
De Serres, Sacha A.
author_facet Bouchard-Boivin, François
Désy, Olivier
Béland, Stéphanie
Houde, Isabelle
De Serres, Sacha A.
author_sort Bouchard-Boivin, François
collection PubMed
description INTRODUCTION: Infections and cancers now outnumber rejection as a cause of morbidity in transplant recipients, likely as a result of over-immunosuppression. Currently, there is no clinical tool to detect over-immunosuppression. We recently reported that tumor necrosis factor alpha (TNF-α) production by CD14(+)CD16(+) intermediate monocytes, following ex vivo stimulation by Epstein-Barr virus–peptides, could identify over-immunosuppressed patients. METHODS: We conducted a pilot study the assay using 142 peripheral blood mononuclear samples from a cohort of 71 kidney transplant recipients. Patients were classified as cases or controls according to the occurrence of opportunistic infection, recurring bacterial infections or de novo neoplasia in the 12 months following blood collection. We used both the classifier rule and a threshold of <73% of CD14(+)CD16(+)TNFα(+) cells developed in a previous training set. RESULTS: Cases were detected with 83% sensitivity and 68% specificity. The negative predictive value of the assay was 89%. The hazard ratio for the occurrence of the endpoint was 6.8 (95% confidence interval 2.0–23.9; P = 0.003) in patients with a positive test. Multivariable linear regression analysis revealed that the association was independent of baseline clinical characteristics, renal function, and immunosuppressive regimen. CONCLUSION: These data validate this cell-based assay as a promising tool for personalizing immunotherapy. Studies are under way for a 2-step assay with improved specificity.
format Online
Article
Text
id pubmed-6829185
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-68291852019-11-07 TNF-α Production by Monocytes Stimulated With Epstein-Barr Virus–Peptides as a Marker of Immunosuppression-Related Adverse Events in Kidney Transplant Recipients Bouchard-Boivin, François Désy, Olivier Béland, Stéphanie Houde, Isabelle De Serres, Sacha A. Kidney Int Rep Translational Research INTRODUCTION: Infections and cancers now outnumber rejection as a cause of morbidity in transplant recipients, likely as a result of over-immunosuppression. Currently, there is no clinical tool to detect over-immunosuppression. We recently reported that tumor necrosis factor alpha (TNF-α) production by CD14(+)CD16(+) intermediate monocytes, following ex vivo stimulation by Epstein-Barr virus–peptides, could identify over-immunosuppressed patients. METHODS: We conducted a pilot study the assay using 142 peripheral blood mononuclear samples from a cohort of 71 kidney transplant recipients. Patients were classified as cases or controls according to the occurrence of opportunistic infection, recurring bacterial infections or de novo neoplasia in the 12 months following blood collection. We used both the classifier rule and a threshold of <73% of CD14(+)CD16(+)TNFα(+) cells developed in a previous training set. RESULTS: Cases were detected with 83% sensitivity and 68% specificity. The negative predictive value of the assay was 89%. The hazard ratio for the occurrence of the endpoint was 6.8 (95% confidence interval 2.0–23.9; P = 0.003) in patients with a positive test. Multivariable linear regression analysis revealed that the association was independent of baseline clinical characteristics, renal function, and immunosuppressive regimen. CONCLUSION: These data validate this cell-based assay as a promising tool for personalizing immunotherapy. Studies are under way for a 2-step assay with improved specificity. Elsevier 2019-07-19 /pmc/articles/PMC6829185/ /pubmed/31701054 http://dx.doi.org/10.1016/j.ekir.2019.07.007 Text en © 2019 International Society of Nephrology. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Translational Research
Bouchard-Boivin, François
Désy, Olivier
Béland, Stéphanie
Houde, Isabelle
De Serres, Sacha A.
TNF-α Production by Monocytes Stimulated With Epstein-Barr Virus–Peptides as a Marker of Immunosuppression-Related Adverse Events in Kidney Transplant Recipients
title TNF-α Production by Monocytes Stimulated With Epstein-Barr Virus–Peptides as a Marker of Immunosuppression-Related Adverse Events in Kidney Transplant Recipients
title_full TNF-α Production by Monocytes Stimulated With Epstein-Barr Virus–Peptides as a Marker of Immunosuppression-Related Adverse Events in Kidney Transplant Recipients
title_fullStr TNF-α Production by Monocytes Stimulated With Epstein-Barr Virus–Peptides as a Marker of Immunosuppression-Related Adverse Events in Kidney Transplant Recipients
title_full_unstemmed TNF-α Production by Monocytes Stimulated With Epstein-Barr Virus–Peptides as a Marker of Immunosuppression-Related Adverse Events in Kidney Transplant Recipients
title_short TNF-α Production by Monocytes Stimulated With Epstein-Barr Virus–Peptides as a Marker of Immunosuppression-Related Adverse Events in Kidney Transplant Recipients
title_sort tnf-α production by monocytes stimulated with epstein-barr virus–peptides as a marker of immunosuppression-related adverse events in kidney transplant recipients
topic Translational Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829185/
https://www.ncbi.nlm.nih.gov/pubmed/31701054
http://dx.doi.org/10.1016/j.ekir.2019.07.007
work_keys_str_mv AT bouchardboivinfrancois tnfaproductionbymonocytesstimulatedwithepsteinbarrviruspeptidesasamarkerofimmunosuppressionrelatedadverseeventsinkidneytransplantrecipients
AT desyolivier tnfaproductionbymonocytesstimulatedwithepsteinbarrviruspeptidesasamarkerofimmunosuppressionrelatedadverseeventsinkidneytransplantrecipients
AT belandstephanie tnfaproductionbymonocytesstimulatedwithepsteinbarrviruspeptidesasamarkerofimmunosuppressionrelatedadverseeventsinkidneytransplantrecipients
AT houdeisabelle tnfaproductionbymonocytesstimulatedwithepsteinbarrviruspeptidesasamarkerofimmunosuppressionrelatedadverseeventsinkidneytransplantrecipients
AT deserressachaa tnfaproductionbymonocytesstimulatedwithepsteinbarrviruspeptidesasamarkerofimmunosuppressionrelatedadverseeventsinkidneytransplantrecipients